From GlobeNewswire: 2025-05-08 08:00:00

Artiva Biotherapeutics, Inc. announces IND clearance for a global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, myositis, and systemic sclerosis. The trial marks the first exploration of an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren’s disease in the U.S. Initial safety and translational data to be presented by year-end 2025, with clinical response data expected in 1H2026.

Longer-term clinical data from a Phase 1/2 trial exploring AlloNK + rituximab in B-NHL demonstrates complete response rates and median duration of responses in line with approved auto-CAR-T therapies, supporting deep B-cell depletion. Cash runway extended into Q2 2027, with $166.0 million in cash, cash equivalents, and investments as of March 31, 2025.

Artiva Biotherapeutics emphasizes their commitment to developing effective, safe, and accessible cell therapies for autoimmune diseases and cancers. They have initiated regulatory submissions globally for a basket trial exploring AlloNK® in refractory rheumatoid arthritis, Sjögren’s disease, myositis, and systemic sclerosis. The company-sponsored trial in the U.S. aims to provide ease of use and a well-tolerated safety profile.

Initial safety and translational data for AlloNK + rituximab across multiple autoimmune indications will be shared by the end of 2025. The first half of 2026 will see the disclosure of clinical response data in the lead autoimmune indication, supporting AlloNK’s emerging target product profile. The company also plans to announce its lead indication for further development.

Financially, Artiva Biotherapeutics reports having $166.0 million in cash, cash equivalents, and investments as of March 31, 2025, providing funding into Q2 2027. Research and development expenses for the first quarter were $17.1 million, with a net loss of $20.3 million. The company continues to focus on advancing AlloNK in autoimmune disease and generating meaningful data sets.



Read more at GlobeNewswire:: Artiva Biotherapeutics Reports First Quarter 2025 Financial